Home › Nierkanker (niercelcarcinoom) › Florida › Jacksonville
Nierkanker (niercelcarcinoom) klinische studies in Jacksonville, FL
14 studies voor Nierkanker (niercelcarcinoom) zoeken deelnemers op locaties in en rond Jacksonville (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RekruterenFase 2
- Mayo Clinic in Florida, Jacksonville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruterenFase 1
- Mayo Clinic Florida, Jacksonville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruterenFase 1
- Exelixis Clinical Site #78, Jacksonville
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekruterenFase 2
- Mayo Clinic in Florida, Jacksonville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruterenObservatieonderzoek
- Mayo Clinic Jacksonville, Jacksonville
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekruterenFase 2
- Mayo Clinic in Florida, Jacksonville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruterenFase 1/2
- Mayo Clinic Pharmacy, Jacksonville
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
RekruterenFase 1/2
- Mayo Clinic in Florida, Jacksonville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruterenFase 1
- Xencor Investigative Site, Jacksonville
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekruterenFase 1/2
- Mayo Clinic Jacksonville, Jacksonville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruterenFase 1
- Mayo Clinic Comprehensive Cancer Center, Jacksonville
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RekruterenObservatieonderzoek
- Mayo Clinic in Florida, Jacksonville
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruterenFase 1/2
- Mayo Clinic, Jacksonville
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekruterenFase 1/2
- Mayo Clinic in Florida, Jacksonville
Nierkanker (niercelcarcinoom) studies in andere steden
- Houston, TX35 studies
- New York City, NY27 studies
- Nashville, TN23 studies
- Dallas, TX23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Pittsburgh, PA15 studies
- Philadelphia, PA15 studies
- Queens, NY15 studies
- Rochester, MN14 studies
Andere studies in Jacksonville
- Borstkanker40 studies
- Niet-kleincellige longkanker39 studies
- Kanker (alle vormen)29 studies
- Metastatische kanker28 studies
- Colorectale kanker27 studies
- Prostaatkanker26 studies
- Obesitas25 studies
- Hartfalen21 studies
- Aldermeesklierkanker20 studies
- Overgewicht19 studies
- Multipel myeloom18 studies
- Longkanker17 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.